EOLS · Company research
Evolus, Inc. Common Stock (EOLS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) stock price, news, quote and history - Yahoo Finance UK | Evolus, Inc. (EOLS) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 15, 2026 | neutral | 0 | 0.6 |
| Evolus, Inc. (EOLS) Stock Price, News, Quote & History - Yahoo! Finance Canada | Evolus, Inc. (EOLS) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| UTMD Trades at a Premium to the Industry: How to Play the Stock? | Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bearish | -0.333 | 1 |
| UTMD Trades at a Premium to the Industry: How to Play the Stock? | Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bearish | -0.333 | 1 |
| Evolus Stock Price Forecast. Should You Buy EOLS? - StockInvest.us | Evolus Stock Price Forecast. Should You Buy EOLS? StockInvest.us | View source ↗ | StockInvest.us | Oct 2, 2026 | neutral | 0 | 0.6 |
| Evolus gets FDA warnings over Jeuveau IG post (EOLS:NASDAQ) - Seeking Alpha | Evolus gets FDA warnings over Jeuveau IG post (EOLS:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 2, 2026 | neutral | 0 | 0.6 |
| At participating practices, each patient check-in will send $1 to cancer support. - Stock Titan | At participating practices, each patient check-in will send $1 to cancer support. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Evolus Inc (NASDAQ:EOLS) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill | Evolus Inc (NASDAQ:EOLS) Passes Minervini Trend Template and High Growth Momentum Screen ChartMill | View source ↗ | ChartMill | Oct 1, 2026 | neutral | 0 | 0.6 |
| Evolus Inc. (EOLS) Trades Near $7.97 as Market Weighs Next Move Toward $8.37 Resistance - Breadth Thrust - https://www.siam.in/ | Evolus Inc. (EOLS) Trades Near $7.97 as Market Weighs Next Move Toward $8.37 Resistance - Breadth Thrust https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Sep 28, 2026 | neutral | 0 | 0.6 |
| Insider at Evolus (NASDAQ: EOLS) moves to sell nearly $1M in stock - Stock Titan | Insider at Evolus (NASDAQ: EOLS) moves to sell nearly $1M in stock Stock Titan | View source ↗ | Stock Titan | Sep 2, 2026 | neutral | 0 | 0.6 |
| Biotech Stocks At 52-Week Highs - RNXT +15%, EOLS, CRNX, APGE - RTTNews | Biotech Stocks At 52-Week Highs - RNXT +15%, EOLS, CRNX, APGE RTTNews | View source ↗ | RTTNews | Sep 1, 2026 | neutral | 0 | 0.6 |
| Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet - Yahoo Finance | Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet Yahoo Finance | View source ↗ | Yahoo Finance | Aug 27, 2026 | neutral | 0 | 0.6 |
| Evolus (EOLS) Stock Jumps On Margin Turn And EBITDA Momentum - Simply Wall Street | Evolus (EOLS) Stock Jumps On Margin Turn And EBITDA Momentum Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses - Quiver Quantitative | Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 5, 2026 | neutral | 0 | 0.6 |
| EOLS Forecast — Price Target — Prediction for 2027 - TradingView | EOLS Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Evolus Inc. (EOLS) stock falls on Q1 2026 Earnings - Quiver Quantitative | Evolus Inc. (EOLS) stock falls on Q1 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | May 4, 2026 | neutral | 0 | 0.6 |
| Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance | Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | May 4, 2026 | neutral | 0 | 0.6 |
| How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions - Yahoo Finance | How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions Yahoo Finance | View source ↗ | Yahoo Finance | Apr 25, 2026 | neutral | 0 | 0.6 |
| Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings - Quiver Quantitative | Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Mar 3, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.